ALMIRALL: 4Q’24 RESULTS (ANÁLISIS BANCO SABADELL)
4Q'24 vs. 4Q'23 ResultsSales: € 258.1 M (+17.4% vs. +12.2% BS(e) and +13.5% consensus);
EBITDA: € 50.4 M (+40.8% vs. +29.9% BS(e) and +24.6% consensus);
EBIT: € 15.0 M (+177.8% vs. +113.0% BS(e) and +172.2% consensus);
Net Profit: € 0.2 M (€ -52.1 M in FY2023 vs. € 2.5 M BS(e) and € 7.9 M consensus);
FY2024 vs. FY2023 Results
Sales: € 985.7 M (+10.2% vs. +8.9% BS(e) and +9.2% consensus);
EBITDA: € 192.6 M (+10.6% vs. +8.4% BS(e) and +7.3% consensus);
EBIT: € 53.5 M (+7.4% vs. +0.4% BS(e) and +6.8% consensus);
Net Profit: € 10.1 M (€ -38.5 M in FY2023 vs. € 12.4 M BS(e) and € 17.8 M consensus);
Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.